

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James R. Matson et al.  
Serial No.: 10/826,736  
Date Filed: April 16, 2004  
Examiner: Unassigned  
Group Art Unit: 3762  
Confirmation No.: 1355  
Title: **HEMOFILTRATION SYSTEMS, METHODS,  
AND DEVICES USED TO TREAT  
INFLAMMATORY MEDIATOR RELATED  
DISEASE**

**MAIL STOP - AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**


Applicants respectfully request, pursuant to 37 C.F.R. §1.56, 1.97 and 1.98, that the references listed on the attached PTO-1449 form be considered and cited in the examination of the above-identified application. Pursuant to 37 C.F.R. §1.98(a)(2), a legible copy of any foreign patent, unpublished U.S. application, and/or non-patent published document cited on the attached PTO Form 1449 is being submitted with this Information Disclosure Statement. Consistent with the provisions of 37 C.F.R. §1.97(h), this submission does not constitute an admission or representation that the submitted reference(s) is/are material to the patentability of the subject matter disclosed in the application.

Applicants believe that no fees are due at this time, however, the Commissioner is hereby authorized to charge any fees or credit overpayments to Deposit Account No. 50-2148 of Baker Botts L.L.P. in order to effectuate this filing.

If there are any matters concerning this Application that may be cleared up in a telephone conversation, please contact Applicants' attorney at 512.322.2599.

Respectfully submitted,

BAKER BOTTS L.L.P.  
Attorneys for Applicants

  
Thomas R. Felger  
Reg. No. 28,842

Date: 22 MAY 2007

SEND CORRESPONDENCE TO:

Baker Botts L.L.P.

Customer Number **31625**

512.322.2599

512.322.8383 (Fax)

<b>PTO-1449</b>  <b>Information Disclosure Citation in an Application</b>			Application No.		Applicant(s)		
			10/826,736		James R. Matson et al.		
			Docket Number		Group Art Unit	Filing Date	
			067062.0129		3762	April 16, 2004	
<b>U.S. PATENT DOCUMENTS</b>							
		<b>DOCUMENT NO.</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE</b>
	A	4708799	11/24/87	Klaus Gerkach et al.	210	500.23	09/17/85
	B	4863609	09/05/89	Roland Schnabel et al.	210	641	11/17/83
	C	5944684	08/31/99	Martin Roberts et al.	604	5	06/02/97
	I	5986062	11/16/99	Ohmura et al.	530	363	10/3/95
	D	2006/0129082	06/15/06	Jacek Rozga	604	6.04	08/11/03
	E						
	F						
	G						
	H						
	I						
	J						
	K						
	L						
	M						
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>DOCUMENT NO.</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION</b>
							<b>YES</b> <b>NO</b>
	N	2124511A	02/22/84	GB	A61M	1/03	X
	O						
	P						
	Q						
	R						
	S						
<b>NON-PATENT DOCUMENTS</b>							
		<b>DOCUMENT (Including Author, Title, Source, and Pertinent Pages)</b>					<b>DATE</b>
	T	"A Dangerous Error in the Dilution of 25 Percent Albumin", The New England Journal of Medicine, Volume 338:1226-1227, No. 17, 7 <a href="http://content.nejm.org/cgi/content/extract/338/17/1226">http://content.nejm.org/cgi/content/extract/338/17/1226</a> , 2 pgs					4/23/98
	U	ZLB Behring, Albumin (Human) USP, 25 %, Albuminar -25, RX Only, 7 pgs					8/2004
	V						
	W						
	X						
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							